Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic HCV-1b infected patient~* HCV RNA viral load of ≥ 100,000 IU/mL at screening~* Ages 20 to 75 years~* Non-responder to Interferon plus Ribavirin therapy~* Patient who has been excluded from interferon/ribavirin therapy or intolerant for Interferon/Ribavirin therapy~Exclusion Criteria:~Patients who have -~* Hepatocellular carcinoma~* Co-infection with Hepatitis B virus (HBV) or Human Immunodeficiency Virus (HIV)~* Severe or uncontrollable complication

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Daclatasvir + Asunaprevir (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).